Page 6,479«..1020..6,4786,4796,4806,481..6,4906,500..»

'I had a stroke at the age of 21'

Posted: Published on September 24th, 2012

By Jim Taylor Newsbeat reporter Please turn on JavaScript. Media requires JavaScript to play. Twenty-two-year-old Becky Beaumont from Stockport suffers two strokes Suffering a stroke is something you might associate with people in their 60s and 70s but it can happen to anyone. Newsbeat has seen figures showing more than 1,000 under-30s are taken to hospital in England each year after suffering one. Charities say there is still a lack of awareness about stroke, especially among young people. Twenty-two-year-old Becky Beaumont from Stockport admits she had no idea it could happen to someone her age, until she suffered a stroke last October. She says she woke up one morning and found she couldn't move. "I shouted for my mum and when she came in, I could see the panic on her face," she said. "It was terrifying." She was temporarily paralysed on her left side and has spent the last year trying to build up movement and strength in her arm and leg. Read more from the original source: 'I had a stroke at the age of 21' … Continue reading →

Comments Off on 'I had a stroke at the age of 21'

Michael Parkinson, Fiona Phillips and Gordon Banks join forces to fight dementia

Posted: Published on September 24th, 2012

A Day To Remember is a campaign to drive awareness of dementia, launched bythe Department of Health with support from the Alzheimers Society. Itaims to increase early diagnosis rates for dementia across England by tackling the publics fears of talking about the condition. New research shows: Half of people (50 percent) say they would find it hard to talk about dementia to a friend or family member they thought might have it; A third (33 percent) say that personal concerns (such as fear of upsetting someone or feeling awkward or anxious) would discourage them from talking about dementia or memory loss with a friend or relative. That nearly two-thirds (63 percent) of people would not be confident telling the difference between the signs of dementia and the normal signs of ageing. Sir Michael Parkinson, Fiona Phillipsand Gordon Banks join forces in this video to talk about their experiences of alzheimer's and dementia in their families. They also discuss the importance of speaking up if you think a member of your family might be suffering from the condition, because early diagnosis can make the world of difference when it comes to treatment. To learn more about A Day To Remember head … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Michael Parkinson, Fiona Phillips and Gordon Banks join forces to fight dementia

Amarantus BioSciences Announces the Release of Research Report by OneMedPlace

Posted: Published on September 24th, 2012

SUNNYVALE, Calif., Sept. 24, 2012 /PRNewswire/ --Amarantus BioSciences, Inc. (AMBS), a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson's disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research. The report can be found at http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf. The report states: "Treatment with MANF prior to inducing PD-like conditions in animals protected the subjects from the onset of neuron degeneration. Even more impressively, in animals where Parkinson's was already present, treatment with MANF provided restorative benefits that included regaining motor function, as well as the maintenance and increase in function of the neurons that were still present. Cumulatively, these studies provide strong evidence that MANF has the potential to serve as a first-in-class curative treatment for degenerative neurological disorders that include PD. Amarantus is currently in the design and development stages to move MANF into clinical trials." The report also states: "Amarantus owns the license for Power3 Medical Products' NuroPro Blood Test as it relates to Parkinson's disease. NuroPro is a diagnostic platform for the early detection of neurodegenerative diseases. The PD application of this diagnostic has completed proof-of-concept and Phase I clinical validation studies." About Amarantus BioSciences, Inc. … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Amarantus BioSciences Announces the Release of Research Report by OneMedPlace

Bucklew runs against Parkinson’s

Posted: Published on September 24th, 2012

BY KATHY ROUTLIFFE | kroutliffe@pioneerlocal.com September 24, 2012 8:58AM Evan Bucklew, 6, and sister Madeleine, 8, cheered on their dad Bill Bucklew, who completed the Sept. 9 Ironman Wisconsin triathlon. Bucklew, of Wilmette, raised $3,400 for Parkinson's disease research on behalf of the Michael J. Fox Foundation.Evan Bucklew, 6, and sister Madeleine, 8, cheered on their dad Bill Bucklew, who completed the Sept. 9 Ironman Wisconsin triathlon. Bucklew, of Wilmette, raised $3,400 for Parkinson's disease research on behalf of the Michael J. Fox Foundation.Evan Bucklew, 6, and sister Madeleine, 8, cheered on their dad Bill Bucklew, who completed the Sept. 9 Ironman Wisconsin triathlon. Bucklew, of Wilmette, raised $3,400 for Parkinson's disease research on behalf of the Michael J. Fox Foundation. storyidforme: 36912372 tmspicid: 13488985 fileheaderid: 6223947 WHO: Bill Bucklew WHAT: Wisconsin Ironman WHY: Raising money for Parkinsons research HOMETOWN: Wilmette To learn more about Parkinsons disease and the Michael J. Fox Foundation, visit http://www.michaeljfox.org/. To donate in Bucklews effort, visit www2.michaeljfox.org/site/TR/TeamFox/TeamFox?px=1607346&pg=personal&fr_id=1053 . Read more: Bucklew runs against Parkinson’s … Continue reading →

Posted in Parkinson's Treatment | Comments Off on Bucklew runs against Parkinson’s

Five questions with Col. Dallas Hack

Posted: Published on September 24th, 2012

Courtesy Photo Hack What do you think has contributed to the greater awareness of traumatic brain injuries in recent years? The media attention to the care of Wounded Warriors in 2007 focused awareness on several issues including traumatic brain injury, calling TBI the signature wound of the conflicts in Iraq and Afghanistan. This led to a large appropriation to improve the care for TBI and psychological health and to significantly accelerate research in these areas. This was followed by increasing scrutiny of traumatic brain injuries in sports. What are some of the most promising fields of research? Improved screening and diagnostic tools for TBI show the most promise for early advances in care for traumatic brain injury. Much work is being done to develop improved treatments, including pharmaceuticals and advanced rehabilitation, but this will take somewhat longer to reach the clinic. What are some of the ways in which the Army is studying mild traumatic brain injury? More than 500 research projects in traumatic brain injury have been undertaken since 2007, almost half of which study mild TBI. Most of these projects are performed by partnering with academic researchers throughout the U.S. As a leader in the field, how far … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Five questions with Col. Dallas Hack

Zyomyx, Inc. Announces Appointment of Chief Financial Officer

Posted: Published on September 24th, 2012

FREMONT, Calif., Sept. 24, 2012 (GLOBE NEWSWIRE) -- Zyomyx, Inc., an innovator in the development and commercialization of proprietary diagnostic platforms, has appointed Jennifer McFarlane as Chief Financial Officer (CFO). Ms. McFarlane brings 25 years of experience in finance and global investment banking. In total, she has helped raise more than US$600 million, primarily for early-stage companies, and close approximately 15 mergers and acquisitions (M&A). At Zyomyx, Ms. McFarlane will be responsible for financial operations, investor relations and capital raising. Prior to joining Zyomyx, Ms. McFarlane was CFO at LanzaTech, where she built infrastructure to support the company's initial sales on three continents. Previous positions also include CEO of Astia, a nonprofit accelerator focused on high-growth, women-led startups; Executive Director of Southern Pacific Petroleum, a public energy technology company in Australia; and Vice President of Investment Banking at Salomon Brothers, now Citigroup. Ms. McFarlane has also worked with the Barents Group of KPMG Consulting, providing strategic advice and M&A services to corporations and governments across seven emerging economies. "Jennifer's experience working in emerging markets and with public- and private-sector companies will be a tremendous asset," said Peter Wagner, Zyomyx's CEO. "She will undoubtedly help drive our commercial success, particularly as … Continue reading →

Posted in MS Treatment | Comments Off on Zyomyx, Inc. Announces Appointment of Chief Financial Officer

Cancer Stem Cells Drug Pipeline Update 2012

Posted: Published on September 24th, 2012

NEW YORK, Sept. 24, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cancer Stem Cells Drug Pipeline Update 2012 http://www.reportlinker.com/p0980850/Cancer-Stem-Cells-Drug-Pipeline-Update-2012.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biological_Therapy Treatments designed to target and destroy cancer stem cells may come to revolutionize how we treat cancer. This unique product covers both explicit cancer stem cell drug development and cancer drugs which are inhibitors of the Hedgehog, Notch, and WNT Pathway. These developmental pathways are frequently activated in neoplasms, and particularly in the rare subpopulation of cancer stem cells. There are today 203 companies plus partners developing 243 cancer stem cells and developmental pathways drugs in 684 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 123 drugs. Cancer Stem Cells Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 165 different targets. These targets are further categorized on in the software application by 38 classifications of molecular function and with pathway referrals to BioCarta, KEGG and NetPath. How May Drug Pipeline Update Be of Use? * Show investors/board/management that you are right … Continue reading →

Posted in Stem Cell Research | Comments Off on Cancer Stem Cells Drug Pipeline Update 2012

Therapeutic impact of cell transplantation aided by magnetic factor

Posted: Published on September 24th, 2012

Public release date: 24-Sep-2012 [ | E-mail | Share ] Contact: David Eve celltransplantation@gmail.com Cell Transplantation Center of Excellence for Aging and Brain Repair Putnam Valley, NY. (Sept. 24, 2012) Two studies in the current issue of Cell Transplantation (21:6), now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/, demonstrate how the use of magnetic particles are a factor that can positively impact on the targeted delivery of transplanted stem cells and to also provide better cell retention. A research team from the University of British Columbia used focused magnetic stem cell targeting to improve the delivery and transport of mensenchymal stem cells to the retinas of test rats while researchers from Cedars-Sinai Heart Institute (Los Angeles) injected magnetically enhanced cardiac stem cells to guide the cells to their target to increase cell retention and therapeutic benefit in rat models of ischemic/reperfusion injury. According to study co-author Dr. Kevin Gregory-Evans, MD, PhD, of the Centre for Macular Degeneration at the University of British Columbia, degeneration of the retina - the cause of macular degeneration as well as other eye diseases - accounts for most cases of blindness in the developed world. To date, the transplantation of mensenchymal stem cells to the damaged retina … Continue reading →

Posted in Stem Cell Research | Comments Off on Therapeutic impact of cell transplantation aided by magnetic factor

Sugary Sodas Lead To An Increased Risk Of Obesity

Posted: Published on September 24th, 2012

September 24, 2012 Lee Rannals for redOrbit.com Your Universe Online A new study has confirmed a link between sugary sodas, and genetic susceptibility to high body mass index (BMI) and increased risk of obesity. The team wrote in the New England Journal of Medicine that their findings reinforce the view that environmental and genetic factors shape obesity risk. Our study for the first time provides reproducible evidence from three prospective cohorts to show genetic and dietary factorssugar-sweetened beveragesmay mutually influence their effects on body weight and obesity risk, Lu Qi, assistant professor in the Department of Nutrition at Harvard School of Public Health (HSPH) and senior author of the study, said in a press release. Consuming sugary drinks in the past three decades has increased worldwide, and there has been little research on whether environmental factors like drinking these drinks can influence genetic predisposition. For the study, the team used data from 121,700 women in the Nurses Health Study (NHS), 51,529 men in the Health Professionals Follow-up Study (HPFS), and 25,000 in the Womens Genome Health Study (WGHS). All of the participants in the research had completed food-frequency questionnaires detailing their food and drink consumption. The team analyzed data from … Continue reading →

Comments Off on Sugary Sodas Lead To An Increased Risk Of Obesity

New back pain gene identified in largest genetic study of its kind

Posted: Published on September 24th, 2012

Public release date: 24-Sep-2012 [ | E-mail | Share ] Contact: Katherine Barnes katherine.barnes@kcl.ac.uk 44-207-848-3076 King's College London Researchers at King's College London have for the first time identified a gene linked to age-related degeneration of the intervertebral discs in the spine, a common cause of lower back pain. Costing the UK an estimated 7billion a year due to sickness leave and treatment costs, the causes of back pain are not yet fully understood. Until now, the genetic cause of lower back pain associated with lumbar disc degeneration (LDD) was unknown, but the largest study to date, published this week in the journal Annals of Rheumatic Diseases, has revealed an association with the PARK2 gene. The researchers, funded by the Wellcome Trust and Arthritis Research UK, say more research into this surprising association needs to be carried out in order to fully understand how it is triggered, but this new finding could ultimately pave the way towards developing new treatments in the future. LDD is a common age-related trait, with over a third of middle-aged women having at least one degenerate disc in the spine. Discs become dehydrated, lose height and the vertebrae next to the discs develop bony growths … Continue reading →

Comments Off on New back pain gene identified in largest genetic study of its kind

Page 6,479«..1020..6,4786,4796,4806,481..6,4906,500..»